JMP keeps Cubist at strong buy

JMP Securities analyst Adam Cutler reiterated Cubist Pharmaceuticals Inc. at a strong buy rating on the label inclusion of bacteremia and right-sided endocarditis. The analyst is maintaining a Cubicin U.S. sales estimate of $200 million for 2006. Shares of the Lexington, Mass., biopharmaceutical products company were up $4.30, or 20.24%, at $25.55 on volume of 5,640,412 shares versus the three-month running average of 810,827 shares. (Nasdaq: CBST)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.